Oestradiol and progesterone are the primary female sex hormones. Besides their role in reproduction, these hormones appear to influence energy metabolism(Reference Leeners, Geary and Tobler1). Thus, pharmacological suppression of progesterone and oestradiol secretion for a short (6 d) and a long (5 months) period decreased RMR in pre-menopausal women(Reference Day, Gozansky and Van Pelt2,Reference Melanson, Gavin and Shea3) , while oestradiol replacement prevented that effect(Reference Melanson, Gavin and Shea3). The extent to which these hormones change from the follicular (FP) to the luteal (LP) phase could elevate RMR, as shown in early studies(Reference Bisdee, James and Shaw4,Reference Mehta and Pande5) . To eliminate the confounding effects of changing hormonal levels, assessing energy expenditure during FP became common practice. However, later studies reported similar RMR along the menstrual cycle(Reference Paolisso, Rizzo and Mazziotti6,Reference Piers, Diggavi and Rijskamp7) . A systematic review analysed these conflicting findings to determine the difference in RMR between menstrual phases and define the relevance of the phase when measuring RMR(Reference Benton, Hutchins and Dawes8). The analysis showed lower RMR in the FP v. LP, a pattern primarily noted in studies conducted before 2000(Reference Benton, Hutchins and Dawes8). Notably, most studies qualified as low quality and none as high quality. Lack of objective verification of the menstrual phase, underpowered sample size (<10 subjects) and insufficient control (or poor reporting) of known RMR confounders were the main study flaws(Reference Benton, Hutchins and Dawes8). The reliability and accuracy of the indirect calorimetry systems to detect changes in RMR may be another factor in play(Reference Alcantara, Galgani and Jurado-Fasoli9–Reference Schadewaldt, Nowotny and Strassburger11). Indeed, some metabolic carts have shown insufficient analytical accuracy and reliability(Reference Alcantara, Galgani and Jurado-Fasoli9,Reference Galgani and Castro-Sepulveda10,Reference Cooper, Watras and O’Brien12,Reference Kaviani, Schoeller and Ravussin13) . This analytical issue led Schadewaldt et al. (Reference Schadewaldt, Nowotny and Strassburger11) to propose a method to correct indirect calorimetry data. By simulating VO2 and VCO2 rates after the subject’s testing through mass-flow regulators and pure gases, the analytical error can be calculated to correct the subject’s indirect calorimetry readouts. We applied that procedure to assess gas exchange in both menstrual cycle phases.
Energy intake also appears to change during the menstrual cycle, increasing from the FP to the LP(Reference McNeil and Doucet14,Reference Davidsen, Vistisen and Astrup15) . This increase seems higher when energy intake is measured through self- or interview-based food records (∼660−2090 kJ/d)(Reference Dalvit16–Reference Martini, Lampe and Slavin22) compared with objectively measured food intake (∼380 kJ/d)(Reference Lissner, Stevens and Levitsky23,Reference Tarasuk and Beaton24) . Changes in food and macronutrient preferences during the menstrual cycle show a less consistent pattern. Some studies reported lower consumption and preference for sweet foods during the FP than in the LP(Reference Bowen and Grunberg25), whereas others did not detect differences(Reference McVay, Copeland and Newman26,Reference Lefebvre, Hengartner and Tronci27) . Inconclusive evidence may result from the subjective nature of these measurements. Using alternative methods, such as sucrose threshold determination (i.e. minimal detectable sucrose concentration), Than et al. observed a lower threshold during the FP v. LP(Reference Than, Delay and Maier28). Whether such a change in the sucrose threshold was associated with a different energy/macronutrient intake or sweet food preferences was not determined.
This study aimed to compare RMR and sweet taste preference between the FP and LP in healthy women. To that end, we assessed RMR, sweet taste preference and energy intake in healthy women on a day representative of their FP (days 5–12) and LP (days 20–25) phases. We also assessed the fasting RQ, an index of the proportion of carbohydrates and fats being oxidised for ATP production. RQ is sensitive to the energy balance and dietary macronutrient composition(Reference Miles-Chan, Dulloo and Schutz29,Reference Schutz30) , thus representing a valuable tool to estimate changes in these variables along the menstrual cycle. Circulating fibroblast growth factor 21 (FGF21) concentration was also determined. This hepatokine plays a role in energy balance and fuel oxidation(Reference Jin, Yang and Geng31). FGF21 also suppresses sugar preference in animals and humans(Reference Jensen-Cody, Flippo and Claflin32,Reference Baruch, Wong and Chinn33) . Importantly, to improve those aspects detected as insufficient in previous studies(Reference Benton, Hutchins and Dawes8), our design included verification of a biphasic cycle and a more accurate indirect calorimetry system(Reference Galgani and Castro-Sepulveda10).
Methods
Participants
Women were recruited by public advertising and invited to a screening visit. They had to be healthy according to face-to-face interviews about their past and current health status. They were excluded if reporting current or history of any of these conditions/diseases: high blood pressure, heart disease, diabetes mellitus, endocrine disease, gastrointestinal disease, dyslipidaemia, gynaecological disease including polycystic ovary syndrome, psychiatric illness and altered food behaviour. Women had to have normal values for routine blood testing, including glucose, urea nitrogen, total bilirubin, Ca, P, total proteins, albumin, cholesterol, thyroid-stimulating hormone, free thyroxine, electrolytes, creatinine, liver enzymes activity and haemogram. Women had regular menstrual cycling (self-reported). Only women with a menstrual cycle of 21 to 35 d (the period between consecutive beginnings of menses) over the last three periods and a maximum variation of 7 d between periods were included. Selected participants were between 18 and 35 years old, had stable body weight (change <3 kg over the past 2 months) and BMI ≥18·5 and <30 kg/m2, were non-smokers and did not engage in vigorous physical activity >7 h/week. Participants were not under pharmacological therapy (including hormonal contraceptives such as pills, patches, injections, or intra-uterine devices over the last 3 months) or were not pregnant or lactating. The Ethical Board at Pontificia Universidad Católica de Chile approved the protocol, and participants provided written informed consent before participation.
Experimental design
The menstrual cycle periodicity of all women was registered for 3 months. Then, the first measurement visit was randomly assigned to either the predicted FP or LP. The session for the predicted FP was scheduled on days 5–12 after the menses. The predicted LP session was scheduled for days 20–25 after the menses (Fig. 1). Participants were instructed to avoid vigorous physical activity the day before the measurement visits and maintain their typical dietary pattern. Foods, alcohol, tobacco and caffeine-containing drinks were not allowed for the last 12 h before testing. On the testing day, participants arrived at ∼08.00 hours and were weighed after emptying their bladders. Only participants with a difference in body weight lower than 2·5 kg from the screening visit were allowed to continue the procedure. Afterward, they rested supine for 30 min under thermoneutral and quiet conditions. Blood pressure, body temperature (axillary) and heart rate were determined after 15 min of initiating resting. After the 30-min resting period, gas exchange was determined for 20 min by indirect calorimetry with a canopy system. Once the gas exchange assessment was completed, the accuracy of the calorimetry system was determined, and individual data were corrected as previously reported(Reference Galgani and Castro-Sepulveda10,Reference Schadewaldt, Nowotny and Strassburger11) . Immediately after the gas exchange assessment (∼09.00 hours), a blood sample was withdrawn to analyse the circulating concentrations of oestradiol, progesterone, insulin, glucose and FGF21. We then determined sweet taste preference by the Monell two-series forced-choice tracking procedure(Reference Mennella, Lukasewycz and Griffith34). Finally, a dietitian conducted a 24-h dietary recall of the previous day.
Gas exchange measurement and correction
Gas exchange was determined with a VMax Encore 29n (SensorMedics Co.). The instrument has an IR CO2 analyser (±0·02 % accuracy, 0·01 % resolution) and an electrochemical sensor for O2 detection (galvanic fuel cell; ±0·02 % accuracy, 0·01 % resolution). The flow rate was adjusted to maintain the fraction of expired CO2 between 0·5 % and 1·0 %. The precision of the instrument was 1·1 % for O2 consumption (VO2) and 1·2 % for CO2 production (VCO2), calculated from simulations of VO2 and VCO2 through infusions of N2/CO2 mixtures.
We performed calorimetric corrections of all gas exchange measurements by determining the accuracy of the VO2 consumption and VCO2 production analyses. Analytical accuracy was determined by simulating VO2 and VCO2 exchange through the infusion of pure N2 (>99·999 %) and pure CO2 (>99·9999 %) into the calorimeter hose using high-precision mass-flow regulators (series 358; 0–2 l/min; Analyt-MTC). The difference between expected and measured VO2 and VCO2 was used to correct the data of the participants, as previously described(Reference Galgani and Castro-Sepulveda10). RMR (in kJ/d) was calculated as: (3·941 × VO2 (l/d) + 1·106 × VCO2 (l/d)) × 4.184(Reference Jequier, Acheson and Schutz35). RQ was calculated as the VCO2-to-VO2 ratio(Reference Jequier, Acheson and Schutz35). Gas exchange assessments yielding RQ values equal to or higher than 1·00 were excluded from RMR and RQ analysis.
Circulating concentrations of hormones and metabolites
Serum progesterone, oestradiol and insulin were measured by the chemiluminescent method, while serum FGF21 was measured by ELISA (R&D systems). Plasma glucose was determined by the glucose oxidase method. The HOMA index of insulin resistance was calculated as described elsewhere(Reference Matthews, Hosker and Rudenski36). Blood progesterone concentration ≥5 ng/ml during the predicted LP was considered indicative of ovulation(Reference Schliep, Mumford and Hammoud37).
Sweet taste preference
Participants were presented with pairs of solutions with different sucrose concentrations, from 3 % to 36 % w/v. The most preferred sweetness intensity was determined by the Monell two-series forced-choice tracking procedure.(Reference Mennella, Lukasewycz and Griffith34).
Dietary energy and macronutrient intake
A dietitian interviewed participants to report their foods/meals and serving size intake for the previous 24 h. Participants were requested to indicate foods and ingredients composing their meals. Food’s energy, macronutrient and total sugars (mono- and di-saccharides) contents were calculated using the USDA Food dataset (https://fdc.nal.usda.gov/). If needed, nutrition facts labels of processed foods were also used. The food quotient was calculated from the relative dietary macronutrient energy composition with a factor of 1·00 for carbohydrates, 0·71 for fat and 0·84 for protein(Reference Livesey and Elia38).
Statistical analysis
Data are expressed as mean values and standard deviations. Statistical analyses were performed using SAS software version 9.2 (SAS Institute) or MedCalc® software version 20.118. Raw values were log10-transformed or ranked as needed before analyses. Paired Student’s t tests were used to assess differences between menstrual phases. Repeated-measures ANOVA (Prox Mixed) was conducted to assess differences between phases according to the presence or absence of ovulation. Thus, a model was developed, including the menstrual phase, presence/absence of ovulation and its interaction. In case of significant interaction, the Tukey test was conducted. Intra-individual variability in RMR was expressed as the sd (in kJ/d). The CV was calculated as described by Fraser and Harris(Reference Fraser and Harris39) and compared by the Forkman test available in MedCalc® software. The relationship between RMR (in kJ/d) and body weight (in kg) according to menstrual phase was compared by ANCOVA. Statistical significance was set at 5 %, while Cohen’s effect size for repeated measures (d rm ) evaluated the clinical significance of differences(Reference Lakens40). A d rm value <0·20, 0·20 to <0·50, 0·50 to <0·80 and ≥0·80 was considered as null, small, moderate and high effect, respectively(Reference Lakens40). Based on the intra-individual variability in RMR from a previous study in men(Reference Galgani, Ryan and Ravussin41), we estimated that twenty women would be needed to detect a difference of 293 kJ/d between menstrual phases, considering Cohen’s effect size of 0·60 (90 % power and 5 % type I error).
Results
Twenty women were included, whose characteristics are shown in Table 1. The interval between the first and second visits was 19 (sd 12) d (range: 10–53). Nine out of twenty women had both visits over the same menstrual cycle, that is, between two menses. Visits for the FP and LP occurred on days 9 (sd 2) (range: 5–12) and 23 (sd 2) (range: 20–25) of the cycle, respectively. In relative terms, the FP and LP occurred at 31 (sd 7) % (range: 19–42) and 78 (sd 8) % (range: 67–91) of their typical menstrual cycle duration, respectively. As expected, FP v. LP was characterised by lower serum progesterone (0·3 (sd 0·1) v. 6·4 (sd 4·9) ng/ml, respectively; P < 0·0001) and oestradiol (85 (sd 61) v. 191 (sd 105) pg/ml, respectively; P < 0·0001) concentrations. Eight out of twenty (40 %) women had serum progesterone concentration lower than 5 ng/ml in the LP, the cutoff established as indicative of ovulation(Reference Schliep, Mumford and Hammoud37). These women are hereafter referred to as ‘women without ovulation’. Those women still showed lower serum progesterone in FP v. LP (0·2 (sd 0·1) v. 1·6 (sd 1·2) ng/ml, respectively; P < 0·001), but such a difference was about one-fifth of the observed in ovulating women. Of note, the entire group showed the typical lower body temperature in the FP v. LP (difference of -0·21 (sd 0·57)°C; P = 0·04; d rm = 0·47), without differences in women with and without evidence of ovulation (-0·21 (sd 0·68) and -0·20 (sd 0·38)°C, respectively; P = 0·97). Women with or without evidence of ovulation had no difference in age (P = 0·91), BMI (P = 0·91), menstrual cycle duration (P = 0·75) and the day of their FP and LP visits expressed in either absolute (P = 0·71) or relative (P = 0·82) terms.
For the FP and LP visits, we noted similar body weight (58·4 (sd 7·0) v. 58·4 (sd 7·1) kg; P = 0·97; d rm = 0·00), diastolic (P = 0·72) and systolic (P = 0·11) blood pressure (data not shown), heart rate (P = 0·17; data not shown), glycaemia (83·7 (sd 5·1) v. 83·3 (sd 4·8) mg/dl; P = 0·70; d rm = 0·08), insulinaemia (4·7 (sd 1·6) v. 5·0 (sd 2·0) µmg/ml; P = 0·44; d rm = 0·15) and the HOMA index (0·97 (sd 0·34) v. 1·02 (sd 0·39); P = 0·48; d rm = 0·14).
RMR and RQ
We excluded one woman from the gas exchange analysis because her RQ was over 1·00 on the FP visit. Thus, data from nineteen women were considered for analysis. RMR was lower in the FP v. LP (5042 (sd 460) v. 5197 (sd 490) kJ/d, respectively; P = 0·04; d rm = 0·33; Fig. 2(a)), reaching a RMR difference (ΔRMR, FP – LP) of -155 (sd 310) kJ/d. Such a difference had borderline significance in women with ovulation (ΔRMR: -243 (sd 163) kJ/d; P = 0·07; d rm = 0·79), whereas it was not significant in women without ovulation (ΔRMR: -34 (sd 427) kJ/d; P = 0·99; d rm = 0·05). In the entire group, intra-individual variability in RMR showed an sd of 243 kJ/d (CV = 4·7 %), with similar values in women with and without ovulation (CV = 4·0 and 5·6 %, respectively; P = 0·31). Regression analysis of the relationship between RMR (in kJ/d) and body weight (in kg) showed similar slopes (FP v. LP, 44 (se 12) v. 43 (se 12) kJ/d per kg; P = 0·95) and intercepts (FP v. LP, 2477 (se 716) v. 2703 (se 707) kJ/d; P = 0·20) between menstrual phases.
RQ showed borderline significant higher values in the FP v. LP (0·84 (sd 0·05) v. 0·81 (sd 0·05), respectively; P = 0·07; d rm = 0·62) (Fig. 2(b)). In women without ovulation, RQ was similar in FP v. LP (0·85 (sd 0·06) v. 0·84 (sd 0·06), respectively; P = 0·99; d rm = 0·20). In turn, women with ovulation showed a pattern similar to the entire group (FP v. LP, 0·84 (sd 0·06) v. 0·79 (sd 0·04), respectively; P = 0·14; d rm = 1·01).
Dietary energy, macronutrient and total sugars intake
Energy intake was similar in the FP and LP (5406 (sd 1398) v. 5912 (sd 1795) kJ/d, respectively; P = 0·34; d rm = 0·32). Likewise, macronutrient intake was similar between menstrual phases as a proportion of total energy intake. Consequently, the food quotient was similar in the FP and LP (0·88 (sd 0·01) and 0·87 (sd 0·02), respectively; P = 0·36; d rm = 0·31). Similar findings were obtained when considering only women with or without ovulation. Energy intake from total sugars (as % total energy intake) was about 20 %, without differences between phases (P = 0·71).
Sweet taste preference and serum fibroblast growth factor 21 concentration
Sweet taste preference was lower in the FP v. LP (12 (sd 8) v. 16 (sd 9) %, respectively; P = 0·04; d rm = 0·47; Fig. 2(c)). Such difference was not observed when the analysis was conducted separately in women without ovulation (P = 0·24) and with ovulation (P = 0·63). In turn, serum FGF21 concentration was higher in the FP v. LP (294 (sd 164) v. 197 (sd 104) pg/ml, respectively; P < 0·01; d rm = 0·66; Fig. 2(d)). This difference was not observed in women without ovulation (P = 0·18; d rm = 0·57), but it reached borderline significance in women with ovulation (P = 0·06; d rm = 0·79). We repeated the analysis after excluding one participant having the highest serum FGF21 concentration (802 pg/ml in the FP; see Fig. 2(d)). Results remained similar for the entire sample and by sub-groups of women with and without ovulation (data not shown).
Discussion
Using a calorimetric system of improved accuracy and sample size ∼2-fold larger than often considered(Reference Benton, Hutchins and Dawes8), we observed that RMR, on average, was lower in the FP v. LP in young women with regular menses. Further analysis showed similar regression equations describing the relationship between RMR (kJ/d) and body weight (kg) between phases. We also noted that the between-phase RMR variation was similar to that observed in men over 5 consecutive days(Reference Galgani, Ryan and Ravussin41). Taken together, the difference in RMR between menstrual phases appears small. We also noted a lower sweet taste preference, higher serum FGF21 concentration and a borderline significant higher RQ in the FP compared with the LP. Since body weight remained stable between phases, the menstrual cycle did not affect the balance between energy intake and expenditure. Such a change in fasting RQ suggests a differential preference for carbohydrates over fat as an oxidative source, which might affect food intake. Nevertheless, energy and macronutrient intakes assessed by dietary recalls remained constant during the menstrual cycle.
Whether RMR fluctuates along the menstrual cycle is controversial, a controversy partially explained by the publication date of studies(Reference Benton, Hutchins and Dawes8). Studies published before 2000 have a ∼2-fold higher likelihood of detecting lower RMR in the FP v. LP than those published after 2000. The quality of the metabolic carts may play a role. The low reproducibility of some metabolic carts(Reference Alcantara, Galgani and Jurado-Fasoli9) probably dampens the capacity to detect changes in RMR during the menstrual cycle. In the present study, we improved gas exchange analysis by determining its accuracy after the assessment of each participant and then correcting the measured values(Reference Alcantara, Galgani and Jurado-Fasoli9,Reference Galgani and Castro-Sepulveda10) . Thus, our findings on RMR should be independent of analytical issues. The difference in average RMR between phases aligns with a recent, well-performed, novel study that determined the sleeping metabolic rate in a metabolic chamber(Reference Zhang, Osumi and Uchizawa42). This study found a lower sleeping metabolic rate in the FP v. LP in healthy young women. The difference averaged ∼-335 kJ/d (∼7 %), with a small-to-moderate size effect (d rm ∼0·50). The lower core body temperature during the FP v. LP (-0·27°C) partially accounted for the difference in sleeping metabolic rate. We observed a smaller difference in body temperature (axillary) between phases (-0·21°C), which would have translated into an RMR difference of ∼-251 kJ/d. Thus, the average difference noted in our study represented one-half of the predicted difference. One can speculate that independent and dependent body temperature mechanisms influence RMR during the menstrual cycle. Taken together, menstrual cycle-related RMR variation appears not higher than other sources of variability, including day-to-day variations noted in men(Reference Galgani, Ryan and Ravussin41,Reference Bader, Bosy-Westphal and Dilba43) and circadian variations reported in men and post-menopausal women(Reference Zitting, Vujovic and Yuan44).
Insufficient power to detect changes in RMR may limit the agreement among studies(Reference Benton, Hutchins and Dawes8). We powered our study to detect a difference of 293 kJ/d between menstrual phases, considering a Cohen’s effect size of 0·60. Such a difference represents the intra-individual CV in RMR often reported in men(Reference Galgani, Ryan and Ravussin41,Reference Bader, Bosy-Westphal and Dilba43) . Our study, including a final sample size of nineteen women, allowed detecting a difference in RMR lower than initially planned. Another methodological factor to consider is verifying the menstrual phase in which RMR is assessed. Blood or urinary sex hormone concentrations can be used to confirm the menstrual phase. Not all studies have applied this procedure(Reference Benton, Hutchins and Dawes8). Our study measured serum sex hormones and used serum progesterone concentration in the predicted LP to verify the occurrence of ovulation(Reference Schliep, Mumford and Hammoud37). Eight out of twenty women had serum progesterone concentrations below the threshold considered suggestive of ovulation (≥5 ng/ml). Still, those eight women showed a statistically different serum progesterone between phases. Eventually, the timing of the testing in non-ovulating and ovulating women could differ, but such a possibility seems unlikely. Indeed, visits occurred at a similar timing of the menstrual cycle in women with and without ovulation. Notably, both sub-groups of women manifested lower body temperature on the FP v. LP visits. However, between-phase differences in RMR, RQ and serum FGF21 concentration were accentuated in women with ovulation. Such observation reinforces the notion that menstrual phase influenced those metabolic changes.
An increase in energy intake has been reported in the transition from the FP to the LP(Reference McNeil and Doucet14,Reference Davidsen, Vistisen and Astrup15) . Those findings often rely on self-records or interview-based food records(Reference Dalvit16–Reference Martini, Lampe and Slavin22), which have poor accuracy, particularly in women(Reference Livingstone and Black45). We did not detect differences in energy, macronutrient and total sugars intake using an interview-based technique. Food preference changes have also been described during the menstrual cycle, but the evidence is controversial(Reference Bowen and Grunberg25–Reference Lefebvre, Hengartner and Tronci27). We assessed sweet taste preference using a non-memory-dependent method. We also measured fasting RQ, representing an indirect marker of the dietary carbohydrate-to-fat oxidation ratio and energy balance. High-carbohydrate/low-fat diets, positive energy balance or both determine higher fasting RQ(Reference Miles-Chan, Dulloo and Schutz29,Reference Schutz30,Reference Goris and Westerterp46,Reference Peronnet and Haman47) . We noted a lower sweet taste preference and a trend towards a higher fasting RQ (P = 0·07) in the FP compared with the LP. None of these changes was accompanied by changes in the dietary carbohydrate-to-fat ratio or total sugars intake measured in both menstrual phases. Thus, the pattern noted for fasting RQ and sweet taste preference may not have translated into changes in food intake. Alternatively, our interview-based food record assessment could be insufficient to detect such dietary changes.
We measured serum FGF21 concentration due to its role in energy metabolism(Reference Jin, Yang and Geng31). Humans treated with FGF21 analogues show a decrease in body weight(Reference Baruch, Wong and Chinn33,Reference Gaich, Chien and Fu48,Reference Talukdar, Zhou and Li49) , hepatic fat content(Reference Sanyal, Charles and Neuschwander-Tetri50) and an increase in circulating adiponectin concentration(Reference Baruch, Wong and Chinn33,Reference Gaich, Chien and Fu48–Reference Charles, Neuschwander-Tetri and Pablo Frias51) . FGF21 has also been shown to suppress sugar preference in animals(Reference Jensen-Cody, Flippo and Claflin32,Reference Talukdar, Owen and Song52,Reference von Holstein-Rathlou, BonDurant and Peltekian53) , while treatment with an FGF21 analogue reduced energy intake and preference for sweet foods in humans with overweight or obesity(Reference Baruch, Wong and Chinn33). Ingestion of sucrose or fructose(Reference Dushay, Toschi and Mitten54,Reference Soberg, Sandholt and Jespersen55) – but not glucose(Reference Soberg, Sandholt and Jespersen55) – also increases circulating FGF21 by 2–3 fold. Thus, the notion has emerged that the excess of mono- or di-saccharides increases FGF21 to suppress sugar intake(Reference von Holstein-Rathlou and Gillum56). In the present study, the higher serum FGF21 concentration and lower sweet taste preference in the FP v. LP appear related. Notably, sweet-disliker v. sweet-liker humans showed a ∼1·5-fold higher circulating fasting FGF21 concentration(Reference Soberg, Sandholt and Jespersen55). Such a difference in circulating FGF21 concentration is close to the menstrual phase-related difference in the current study. Thus, FGF21 could mediate the change in sweet taste preference between the FP and LP. Whether the change in circulating FGF21 and sweet taste preference during the menstrual cycle has any reproductive relevance is unknown. In this regard, oestradiol enhances hepatic expression and production of FGF21 in female mice(Reference Allard, Bonnet and Xu57). As we found lower circulating oestradiol in the FP v. LP, we would expect lower circulating FGF21 as well. However, we found the opposite. Then, the changes in circulating FGF21 seem unrelated to those in circulating oestradiol during the menstrual cycle.
We acknowledge limitations in our study, including that we could not confirm the ovulatory status in all women studied. Still, differential patterns observed for RMR, RQ and circulating FGF21 concentration in women with and without ovulation may reinforce our findings. Another limitation, common in studies evaluating energy and macronutrient intake, is the assessment method based on food intake reports. Finally, our evaluation conducted under fasting conditions would have benefited from a supervised control of the 24–48 h period before assessment.
In conclusion, RMR fluctuates along the menstrual cycle in healthy young women. However, such variation is similar to day-to-day variations described in men or post-menopausal women. Sweet taste preference and fasting fuel oxidation appear sensitive to the transition from the FP to LP. Standardisation of the menstrual phase is preferable for studies involving RMR assessment, especially when fuel oxidation and food behaviour are relevant measurements.
Acknowledgements
This work was supported by ANID/CONICYT FONDECYT Regular 1170117 and 1220551 (J.E.G) and Departamento de Ciencias de la Salud, Proyecto PUENTE-2021 (J.E.G). The funders had no role in data collection, analysis the data or interpretation.
L. M.-V. conceived the study, analysed the data and interpreted the data; C. A. interpreted the data and drafted the manuscript; A. V. interpreted the data and drafted the manuscript; R. F.-V. analysed the data and drafted the manuscript; J. E. G. conceived the study, analysed the data and drafted the manuscript. All authors revised critically the manuscript and approved the final version.
The authors declare that there are no conflicts of interest.